

# Meta H Diekstra

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6877987/publications.pdf>

Version: 2024-02-01

14  
papers

246  
citations

1306789

7  
h-index

1199166

12  
g-index

14  
all docs

14  
docs citations

14  
times ranked

424  
citing authors

#	ARTICLE	IF	CITATIONS
1	CYP3A5 and ABCB1 Polymorphisms as Predictors for Sunitinib Outcome in Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2015, 68, 621-629.	0.9	75
2	Association Analysis of Genetic Polymorphisms in Genes Related to Sunitinib Pharmacokinetics, Specifically Clearance of Sunitinib and SU12662. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 96, 81-89.	2.3	67
3	Sunitinib-induced hypertension in CYP3A4 rs4646437 A-allele carriers with metastatic renal cell carcinoma. <i>Pharmacogenomics Journal</i> , 2017, 17, 42-46.	0.9	21
4	Population Modeling Integrating Pharmacokinetics, Pharmacodynamics, Pharmacogenetics, and Clinical Outcome in Patients With Sunitinib-Treated Cancer. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2017, 6, 604-613.	1.3	20
5	Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 1477-1484.	0.8	19
6	A decade of pharmacogenomics research on tyrosine kinase inhibitors in metastatic renal cell cancer: a systematic review. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 605-618.	1.5	19
7	Description of the EuroTARGET cohort: A European collaborative project on Targeted therapy in renal cell cancer—Genetic- and tumor-related biomarkers for response and toxicity. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 529.e9-529.e16.	0.8	9
8	A Genetic Polymorphism in <i>CTLA-4</i> Is Associated with Overall Survival in Sunitinib-Treated Patients with Clear Cell Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 2350-2356.	3.2	7
9	Evaluation of KDR rs34231037 as a predictor of sunitinib efficacy in patients with metastatic renal cell carcinoma. <i>Pharmacogenetics and Genomics</i> , 2017, 27, 227-231.	0.7	5
10	Letter to the editor: Comments on “A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation”. <i>European Journal of Cancer</i> , 2020, 138, 54-56.	1.3	2
11	What do we need to make genetic biomarker-guided treatment for renal cell carcinoma a reality?. <i>Pharmacogenomics</i> , 2017, 18, 1-4.	0.6	1
12	Genome-Wide Meta-Analysis Identifies Variants in DSCAM and PDLIM3 That Correlate with Efficacy Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib. <i>Cancers</i> , 2022, 14, 2838.	1.7	1
13	Association analysis of polymorphisms in genes related to sunitinib pharmacokinetics.. <i>Journal of Clinical Oncology</i> , 2013, 31, 4580-4580.	0.8	0
14	<i>CYP3A5</i> and <i>ABCB1</i> polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 4548-4548.	0.8	0